NCT02483039

Brief Summary

The primary objective is to evaluate the impact of an AKI Follow-up Clinic on major adverse kidney events (MAKE) in comparison to hospitalized patients surviving an episode of AKI who are not exposed to the AKI Follow-up Clinic intervention.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

4 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 18, 2015

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 26, 2015

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2015

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2018

Completed
4.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

April 19, 2018

Status Verified

April 1, 2018

Enrollment Period

2.8 years

First QC Date

June 18, 2015

Last Update Submit

April 17, 2018

Conditions

Keywords

Acute kidney injuryChronic kidney diseaseQuality improvement

Outcome Measures

Primary Outcomes (1)

  • Proportion with a major adverse kidney event

    Composite of chronic dialysis, chronic kidney disease progression, or death

    1 year after randomization

Secondary Outcomes (18)

  • Proportion with a major adverse kidney event

    30, 90, 365 days, and 5 years following randomization

  • Proportion deceased

    30, 90, 365 days, and 5 years following randomization

  • Proportion who require chronic dialysis

    30, 90, 365 days, and 5 years following randomization

  • Proportion with chronic kidney disease progression using CKD-EPI eGFR equation

    30, 90, 365 days, and 5 years following randomization

  • Time to major adverse kidney event

    5 years following randomization

  • +13 more secondary outcomes

Study Arms (2)

AKI Follow-up Clinic

EXPERIMENTAL

Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. The target appointment date is within 30 days of hospital discharge. Routine laboratory investigations will be performed at minimum every three months. Additional in-person visits with a nephrologist at the AKI Follow-up Clinic will be determined at the local sites based upon the participant's clinical status. If in-person visits at 12, 24, and/or 36 weeks are not necessary given the patient's clinical status, they may be replaced with a telephone visit

Behavioral: AKI Follow-up Clinic

Usual Care

NO INTERVENTION

Participants randomized to this arm will have a letter outlining their AKI diagnosis mailed to their family physician. Participants may still be referred to a nephrologist by their inpatient or outpatient healthcare provider, but these participants will not have access to the AKI Follow-up Clinic. Rather, they will proceed through the standard local nephrology referral pathway. In addition, all usual care participants will be contacted via telephone by study staff every three months to assess their clinical condition and ensure study engagement. All usual care participants will be offered a nephrologist assessment and/or bloodwork one year after randomization to determine if ongoing nephrology care is indicated based upon the same criteria applied to AKI Follow-up Clinic participants.

Interventions

Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. At the AKI Follow-up Clinic, assessment forms that were developed during the pilot study at St. Michael's Hospital may be used, but this decision will be left to individual sites. Routine laboratory investigations will be performed at minimum every three months.

AKI Follow-up Clinic

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 yrs
  • Kidney Disease Improving Global Outcomes (KDIGO) stage 2 AKI and above (including need for dialysis)

You may not qualify if:

  • Kidney transplant recipients
  • Outpatient baseline eGFR under 30mL/min/1.73m2 (by CKD-EPI equation); ignore if baseline serum creatinine is unavailable
  • Patients discharged from hospital with a persistent requirement for renal replacement therapy
  • Clinical diagnosis or suspicion of: glomerulonephritis, vasculitis with kidney involvement, hemolytic-uremic syndrome, polycystic kidney disease, myeloma cast nephropathy
  • Pregnancy
  • Residence at a nursing home facility (rehabilitation and retirement home patients should not be excluded)
  • Palliation as primary goal of care (defined as life expectancy ≤ six months or followed by a palliative care physician)
  • Patients with previously established and ongoing nephrology follow-up (defined as ≥ one outpatient appointment with a nephrologist in the previous 12 months)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Mount Sinai Hospital

Toronto, Ontario, Canada

Location

St. Michael's Hospital

Toronto, Ontario, Canada

Location

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Location

University Health Network

Toronto, Ontario, Canada

Location

Related Publications (1)

  • Robinson C, Hessey E, Nunes S, Dorais M, Chanchlani R, Lacroix J, Jouvet P, Phan V, Zappitelli M. Acute kidney injury in the pediatric intensive care unit: outpatient follow-up. Pediatr Res. 2022 Jan;91(1):209-217. doi: 10.1038/s41390-021-01414-9. Epub 2021 Mar 17.

MeSH Terms

Conditions

Acute Kidney InjuryRenal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Ron Wald, MDCM, MPH

    Unity Health Toronto

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 18, 2015

First Posted

June 26, 2015

Study Start

September 1, 2015

Primary Completion

July 1, 2018

Study Completion

December 1, 2022

Last Updated

April 19, 2018

Record last verified: 2018-04

Locations